Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Executive Changes (Mar 21, 2025)

Reports
Leadership Changes
Filing Date
Filed March 21, 2025
Period End
March 17, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed March 21, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. filed this Form 8-K to report a leadership change.

On March 17, 2025, Michael J. LaBarre, Senior Vice President and Chief Technical Officer, notified the Company of his decision to retire, effective March 17, 2025. The Company thanked Mr. LaBarre for his many years of service and contributions to the Company's ENHANZE drug delivery technology.

The filing is limited to this Item 5.02 disclosure (departure of certain officers). It does not disclose a successor appointment, financial results, or any financial figures, and it contains no financial metrics for investors to evaluate.

For investors, the principal takeaway is the departure of a senior technical executive whose tenure was tied to the ENHANZE technology platform. The filing itself does not state any impact on operations, guidance, or succession plans.

Key Highlights

  1. Michael J. LaBarre, Senior Vice President and Chief Technical Officer, retired effective March 17, 2025.
  2. Mr. LaBarre notified the Company of his retirement decision on March 17, 2025.
  3. The Company acknowledged his many years of service and contributions to the ENHANZE drug delivery technology.
  4. The filing is reported under Item 5.02 (Departure of Directors or Certain Officers).
  5. The filing does not name a successor CTO or describe any interim arrangements.
  6. The 8-K was signed by Mark Snyder, Senior Vice President, General Counsel and Corporate Secretary, and dated March 21, 2025.

Frequently Asked Questions

  1. Who is leaving Halozyme Therapeutics?

    Michael J. LaBarre, Senior Vice President and Chief Technical Officer, is retiring from the Company.

  2. When is the retirement effective?

    The retirement is effective March 17, 2025, the same day Mr. LaBarre notified the Company of his decision.

  3. What was Mr. LaBarre's role related to?

    The filing credits Mr. LaBarre with contributions to the Company's ENHANZE drug delivery technology.

  4. Does the filing name a replacement?

    No. The filing does not identify a successor or describe how the CTO responsibilities will be handled.

  5. Are there any financial details in this filing?

    No. The filing consists only of the Item 5.02 departure disclosure and contains no financial figures.